These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35772418)

  • 1. Evidence supports use of on-demand PrEP for HIV prevention.
    Chow EPF; Fairley CK
    Lancet HIV; 2022 Aug; 9(8):e524-e526. PubMed ID: 35772418
    [No Abstract]   [Full Text] [Related]  

  • 2. [PrEP for HIV prevention, major tool of the global diversified prevention strategy].
    Slama L
    Rev Prat; 2021 Nov; 71(9):957-959. PubMed ID: 35147307
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?
    Landovitz RJ; Grinsztejn B
    J Infect Dis; 2016 May; 213(10):1519-20. PubMed ID: 26681779
    [No Abstract]   [Full Text] [Related]  

  • 4. Awareness, knowledge, and attitudes related to HIV pre-exposure prophylaxis and other prevention strategies among physicians from Brazil and Mexico: cross-sectional web-based survey.
    Vega-Ramirez H; Torres TS; Guillen-Diaz C; Pimenta C; Diaz-Sosa D; Konda KA; da Cunha ARC; Robles-Garcia R; Benedetti M; Hoagland B; Bezerra DRB; Caceres CF; Grinsztejn B; Veloso VG;
    BMC Health Serv Res; 2022 Apr; 22(1):532. PubMed ID: 35459177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key data from AIDS 2022.
    Owen R; Maan I; Waters L
    HIV Med; 2023 May; 24(5):515-520. PubMed ID: 36349523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians.
    Palummieri A; De Carli G; Rosenthal É; Cacoub P; Mussini C; Puro V;
    BMC Infect Dis; 2017 Nov; 17(1):734. PubMed ID: 29179700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PrEP Forum: an on-line debate on pre-exposure prophylaxis in Brazil].
    Queiroz AAFLN; Sousa AFL
    Cad Saude Publica; 2017 Nov; 33(11):e00112516. PubMed ID: 29166481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not as Clear Online? Active Visualization of How PrEP Works in the Body Improves Knowledge But Doesn't Change Behavior.
    Christodoulou J; Vincent E; Shaw E; Jones ASK; Rotheram-Borus MJ
    AIDS Behav; 2023 Apr; 27(4):1116-1122. PubMed ID: 36112258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. News from CROI 2022 - caveats using antiretrovirals as HIV prophylaxis.
    Barreiro P; Soriano V
    AIDS Rev; 2022 Apr; 24(2):98-99. PubMed ID: 35544744
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral pre-exposure prophylaxis for HIV prevention is highly effective in community settings.
    Bazzi AR
    Evid Based Med; 2016 Jun; 21(3):99. PubMed ID: 27029888
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of pre-exposure and post-exposure prophylaxes prevention programme on HIV burden and services in a low-resource setting: a simulation modelling approach.
    Adeoti AO; Demir E; Adeyemi S; Yakutcan U; Kengne AP; Kayode G; Aliyu A; Idika N; Isichei C
    Pan Afr Med J; 2021; 40():163. PubMed ID: 34970405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress and new challenges. HIV: the cure moves closer].
    Leiner P
    MMW Fortschr Med; 2015 Feb; 157(2):29. PubMed ID: 25743508
    [No Abstract]   [Full Text] [Related]  

  • 13. On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know.
    Saberi P; Scott HM
    J Gen Intern Med; 2020 Apr; 35(4):1285-1288. PubMed ID: 31965523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.
    Jain S; Krakower DS; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S200-4. PubMed ID: 25972505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada.
    Billick MJ; Fisher KN; Myers S; Tan DHS; Bogoch II
    J Acquir Immune Defic Syndr; 2023 Nov; 94(3):211-213. PubMed ID: 37850980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Othering discourse and stigma amidst the identity formation process among gays, bisexuals and other men who have sex with men on HIV pre-exposure prophylaxis (PrEP).
    Silva-Brandao RRD; Ianni AMZ
    Cien Saude Colet; 2022 May; 27(5):1965-1974. PubMed ID: 35544823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out.
    Marcus JL; Paltiel AD; Walensky RP
    Clin Infect Dis; 2020 Dec; 71(12):3152-3153. PubMed ID: 32097454
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV Prevention: The Promise of Pre-Exposure Prophylaxis in Singapore.
    Wong CS
    Ann Acad Med Singap; 2017 Jul; 46(7):265-266. PubMed ID: 28821889
    [No Abstract]   [Full Text] [Related]  

  • 19. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
    Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
    Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV prevention with PrEP: Challenges and prospects].
    Guyonvarch O; Vaillant L; Hanslik T; Blanchon T; Rouveix E; Supervie V
    Rev Med Interne; 2021 Apr; 42(4):275-280. PubMed ID: 33127173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.